Dr. Julie A. Barta, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- Jefferson Medical College of Thomas Jefferson University (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 267
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2008Medical school: Jefferson Medical College of Thomas Jefferson University
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
PA license MD454548 -
Critical Care Medicine (Internal Medicine) Physician
PA license MD454548 -
Internal Medicine Physician
PA license MD454548
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Thomas Jefferson University Hospital Philadelphia, PA
Medical groups
- Jefferson University Physicians (1,531 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 267
- Services billed
- 578
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 92 | 74 |
| Established patient office or other outpatient visit, 40-54 minutes | 79 | 62 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 65 | 40 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 53 | 29 |
| New patient office or other outpatient visit, 60-74 minutes | 33 | 33 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 20 | 20 |
| Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making) | 18 | 18 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 17 | 17 |
| New patient office or other outpatient visit, 45-59 minutes | 15 | 15 |
| Established patient office or other outpatient visit, 20-29 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Philadelphia, PA | 280 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Philadelphia, PA | 188 |
| Fluticasone Propionate Other prescribers in Philadelphia, PA | 104 |
| Ventolin Hfa (albuterol sulfate) Other prescribers in Philadelphia, PA | 63 |
| Azelastine Hcl Other prescribers in Philadelphia, PA | 63 |
| Montelukast Sodium Other prescribers in Philadelphia, PA | 57 |
| Fluticasone-Salmeterol (fluticasone propion/salmeterol) Other prescribers in Philadelphia, PA | 51 |
| Omeprazole Other prescribers in Philadelphia, PA | 49 |
| Varenicline Tartrate Other prescribers in Philadelphia, PA | 45 |
| Stiolto Respimat (tiotropium br/olodaterol hcl) Other prescribers in Philadelphia, PA | 43 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $1,343 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $1,343 |
|---|
| Consulting Fee | $1,343 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Mar 2, 2025 | Consulting Fee | $1,343 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $407,050 in research payments for these studies, mostly to the institutions running them.
- Leveraging lung cancer screening to optimise clinical trial screening outcomes and COPD management
AstraZeneca UK Limited - Leveraging Lung Cancer Screening to Optimize Screening Outcomes and COPD
AstraZeneca UK Limited - A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate …
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.